Abstract

Lecanemab-irmb (Leqembi – Eisai/Biogen), the IV amyloid-directed monoclonal antibody that received accelerated approval from the FDA in January 2023 for treatment of early Alzheimer’s disease, has now received full approval from the FDA based on a trial showing that it slowed cognitive and functional decline in patients with mild cognitive impairment (MCI) or mild Alzheimer’s disease dementia and confirmed presence of brain amyloid.

Full Text

Published Version
Open DOI Link

Topics from this Paper

  • Early Alzheimer's Disease
  • Functional Decline In Patients
  • Alzheimer's Disease
  • Mild Cognitive Impairment
  • Full Approval
    • + Show 5 more

Create a personalized feed of these topics

Get Started

Get access to 115M+ research papers

Discover from 40M+ Open access, 2M+ Pre-prints, 9.5M Topics and 32K+ Journals.

Sign Up Now! It's FREE

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?
  • Journal of Biological Chemistry
  • Jan 1, 2021
Relevant
Not Relevant
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease
  • JAMA Neurology
  • Nov 25, 2019
Relevant
Not Relevant
Aducanumab and the “post-amyloid” era of Alzheimer research?
  • Neuron
  • Oct 1, 2021
Relevant
Not Relevant
Impairment in Emotion Recognition Abilities in Patients With Mild Cognitive Impairment, Early and Moderate Alzheimer Disease Compared With Healthy Comparison Subjects
  • The American Journal of Geriatric Psychiatry
  • Dec 1, 2008
Relevant
Not Relevant
Impaired Awareness of Deficits and Neuropsychiatric Symptoms in Early Alzheimer's Disease: The Danish Alzheimer Intervention Study (DAISY)
  • Journal of Neuropsychiatry
  • Feb 1, 2010
Relevant
Not Relevant
Guideline Watch (October 2014): Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias
  • FOCUS
  • Jan 1, 2017
Relevant
Not Relevant
Rac1b Increases with Progressive Tau Pathology within Cholinergic Nucleus Basalis Neurons in Alzheimer's Disease
  • The American Journal of Pathology
  • Feb 1, 2012
Relevant
Not Relevant
Motor/Psychomotor Dysfunction in Normal Aging, Mild Cognitive Decline, and Early Alzheimer's Disease: Diagnostic and Differential Diagnostic Features
  • International Psychogeriatrics
  • Dec 1, 1997
Relevant
Not Relevant
The association between change in motor function and cognition in older adults: a descriptive review
  • Physical Therapy Reviews
  • Apr 1, 2008
Relevant
Not Relevant
Measurement of temporal regional cerebral perfusion with single-photon emission tomography predicts rate of decline in language function and survival in early Alzheimer's disease
  • European Journal of Nuclear Medicine and Molecular Imaging
  • Mar 2, 1999
Relevant
Not Relevant
Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD
  • Brain Research
  • Jun 1, 2009
Relevant
Not Relevant
APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline.
  • Alzheimer's & dementia (New York, N. Y.)
  • Jan 1, 2020
Relevant
Not Relevant
Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease
  • Brain
  • Oct 30, 2013
Relevant
Not Relevant
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
  • The journal of prevention of Alzheimer's disease
  • Jan 1, 2022
Relevant
Not Relevant
The Neutrophil and Platelet to Lymphocyte Ratios in People with Subjective, Mild Cognitive Impairment and Early Alzheimer's Disease
  • European Psychiatry
  • Apr 1, 2017
Relevant
Not Relevant
READ MORE FROM

The Medical letter on drugs and therapeutics

Sulbactam/durlobactam (Xacduro) for Acinetobacter pneumonia.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Shockwave therapy for erectile dysfunction.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
In brief: GI effects of GLP-1 receptor agonists.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Ritlecitinib (Litfulo) for severe alopecia areata.
Open Access
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Addendum.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Etrasimod (Velsipity) for ulcerative colitis.
Open Access
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
COVID-19 update: New Novavax vaccine formulation for 2023-2024.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
Correction.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
In brief: Empagliflozin (Jardiance) for chronic kidney disease.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
Antiviral drugs for influenza for 2023-2024.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant